This stock seems to get some help from its earnings numbers released today. Though was a lousy stock with declines past year, it shows some momentum. TECFIDERA and Biosimilars numbers look good in the Infographic. What's the take? Hope it gains more from its R&D spend, which I must say, keeps increasing on scale year-on-year.
biosimilar upside is limited as BIIB only has commercialization rights in Europe to 3 products.... and one of those products (infliximab) is almost unsaleable due to commoditized pricing... Any other Biosimilars products are owned by bioepis...
